Scarlet-2: A Randomized, Double-Blind,Placebo-Controlled, Phase 3 Study to Assess The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy
Status: Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 13 Nov 2019
Price : $35 *
At a glance
- Drugs Thrombomodulin alfa (Primary)
- Indications Blood coagulation disorders
- Focus Adverse reactions; Therapeutic Use
- Acronyms Scarlet2
- Sponsors Asahi Kasei Pharma America Corp
- 19 Jun 2019 This trial has been discontinued in Spain, according to European Clinical Trials Database.
- 11 Jun 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 07 Jun 2019 This trial has been discontinued in France, according to European Clinical Trials Database.